{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:03:15Z","timestamp":1784250195290,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100012118","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012118","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck & Co., Inc. | Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Immunovaccine"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72125-0","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:51:56Z","timestamp":1778712716000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Maveropepimut-S, pembrolizumab and low dose cyclophosphamide in metastatic ovarian cancer: phase 1\/2 PESCO trial"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3980-034X","authenticated-orcid":false,"given":"Ana C.","family":"Veneziani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Lheureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8640-7148","authenticated-orcid":false,"given":"Douglas G.","family":"Millar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neesha","family":"Dhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0602-8667","authenticated-orcid":false,"given":"Ilaria","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-9762","authenticated-orcid":false,"given":"Ainhoa","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Soberanis Pina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Atale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin-Ling","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle","family":"Ramsahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judy","family":"Quintos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Bowering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pam","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9510-8641","authenticated-orcid":false,"given":"Amit M.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"72125_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"72125_CR2","unstructured":"American Cancer Society. Cancer Facts & Figures 2024 (American Cancer Society, 2024)."},{"key":"72125_CR3","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore, K. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379, 2495\u20132505 (2018).","journal-title":"N. Engl. J. Med."},{"key":"72125_CR4","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N. Engl. J. Med. 381, 2416\u20132428 (2019).","journal-title":"N. Engl. J. Med."},{"key":"72125_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391\u20132402 (2019).","journal-title":"N. Engl. J. Med."},{"key":"72125_CR6","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger, R. A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473\u20132483 (2011).","journal-title":"N. Engl. J. Med."},{"key":"72125_CR7","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484\u20132496 (2011).","journal-title":"N. Engl. J. Med."},{"key":"72125_CR8","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41571-023-00819-1","volume":"20","author":"AC Veneziani","year":"2023","unstructured":"Veneziani, A. C. et al. Heterogeneity and treatment landscape of ovarian carcinoma. Nat. Rev. Clin. Oncol. 20, 820\u2013842 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"72125_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa020177","volume":"348","author":"L Zhang","year":"2003","unstructured":"Zhang, L. et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348, 203\u2013213 (2003).","journal-title":"N. Engl. J. Med."},{"key":"72125_CR10","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","volume":"124","author":"W-T Hwang","year":"2012","unstructured":"Hwang, W.-T., Adams, S. F., Tahirovic, E., Hagemann, I. S. & Coukos, G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol. Oncol. 124, 192\u2013198 (2012).","journal-title":"Gynecol. Oncol."},{"key":"72125_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","volume":"5","author":"ML Disis","year":"2019","unstructured":"Disis, M. L. et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 5, 393 (2019).","journal-title":"JAMA Oncol."},{"key":"72125_CR12","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080\u20131087 (2019).","journal-title":"Ann. Oncol."},{"key":"72125_CR13","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1200\/JCO.21.00334","volume":"39","author":"J Hamanishi","year":"2021","unstructured":"Hamanishi, J. et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA). J. Clin. Oncol. 39, 3671\u20133681 (2021).","journal-title":"J. Clin. Oncol."},{"key":"72125_CR14","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1200\/JCO.21.00306","volume":"39","author":"KN Moore","year":"2021","unstructured":"Moore, K. N. et al. Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050\/GOG 3015\/ENGOT-OV39). J. Clin. Oncol. 39, 1842\u20131855 (2021).","journal-title":"J. Clin. Oncol."},{"key":"72125_CR15","doi-asserted-by":"publisher","first-page":"LBA5506","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5506","volume":"41","author":"P Harter","year":"2023","unstructured":"Harter, P. et al. Durvalumab with paclitaxel\/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1\/2 mutation (non-tBRCAm): results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. J. Clin. Oncol. 41, LBA5506 (2023).","journal-title":"J. Clin. Oncol."},{"key":"72125_CR16","doi-asserted-by":"publisher","first-page":"S1223","DOI":"10.1016\/j.annonc.2024.08.2269","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk, B. J. et al. LBA30 ATHENA-COMBO, a phase III, randomized trial comparing rucaparib (RUCA) + nivolumab (NIVO) combination therapy vs RUCA monotherapy as maintenance treatment in patients (pts) with newly diagnosed ovarian cancer (OC). Ann. Oncol. 35, S1223\u2013S1224 (2024).","journal-title":"Ann. Oncol."},{"key":"72125_CR17","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.annonc.2025.05.009","volume":"36","author":"A-C Hardy-Bessard","year":"2025","unstructured":"Hardy-Bessard, A.-C. et al. Dostarlimab and niraparib in primary advanced ovarian cancer. Ann. Oncol. 36, 1503\u20131513 (2025).","journal-title":"Ann. Oncol."},{"key":"72125_CR18","doi-asserted-by":"publisher","first-page":"S1697","DOI":"10.1016\/j.annonc.2025.09.049","volume":"36","author":"N Colombo","year":"2025","unstructured":"Colombo, N. et al. LBA3 Pembrolizumab vs placebo plus weekly paclitaxel \u00b1 bevacizumab in platinum-resistant recurrent ovarian cancer: Results from the randomized double-blind phase III ENGOT-ov65\/KEYNOTE-B96 study. Ann. Oncol. 36, S1697 (2025).","journal-title":"Ann. Oncol."},{"key":"72125_CR19","doi-asserted-by":"publisher","first-page":"e438592","DOI":"10.1200\/EDBK_438592","volume":"44","author":"S Strum","year":"2024","unstructured":"Strum, S., Andersen, M. H., Svane, I. M., Siu, L. L. & Weber, J. S. State-of-the-art advancements on cancer vaccines and biomarkers. Am. Soc. Clin. Oncol. Educ. Book 44, e438592 (2024).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"72125_CR20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/14728214.2023.2218643","volume":"28","author":"AC Veneziani","year":"2023","unstructured":"Veneziani, A. C., Gonzalez-Ochoa, E. & Oza, A. M. Emerging peptide therapeutics for the treatment of ovarian cancer. Expert Opin. Emerg. Drugs 28, 129\u2013144 (2023).","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"72125_CR21","doi-asserted-by":"publisher","first-page":"e0194463","DOI":"10.1371\/journal.pone.0194463","volume":"13","author":"X He","year":"2018","unstructured":"He, X. et al. Expression and clinical significance of survivin in ovarian cancer: a meta-analysis. PLOS ONE 13, e0194463 (2018).","journal-title":"PLOS ONE"},{"key":"72125_CR22","doi-asserted-by":"publisher","first-page":"314","DOI":"10.7150\/jca.13332","volume":"7","author":"X Chen","year":"2016","unstructured":"Chen, X., Duan, N., Zhang, C. & Zhang, W. Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies. J. Cancer 7, 314\u2013323 (2016).","journal-title":"J. Cancer"},{"key":"72125_CR23","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/sj.bjc.6602332","volume":"92","author":"G Ferrandina","year":"2005","unstructured":"Ferrandina, G. et al. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br. J. Cancer 92, 271\u2013277 (2005).","journal-title":"Br. J. Cancer"},{"key":"72125_CR24","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/01.MP.0000073868.31297.B0","volume":"16","author":"C Cohen","year":"2003","unstructured":"Cohen, C., Lohmann, C. M., Cotsonis, G., Lawson, D. & Santoianni, R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod. Pathol. 16, 574\u2013583 (2003).","journal-title":"Mod. Pathol."},{"key":"72125_CR25","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1007\/s00018-002-8518-3","volume":"59","author":"N Zaffaroni","year":"2002","unstructured":"Zaffaroni, N. et al. Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell. Mol. Life Sci. 59, 1406\u20131412 (2002).","journal-title":"Cell. Mol. Life Sci."},{"key":"72125_CR26","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40425-016-0169-2","volume":"4","author":"GM Weir","year":"2016","unstructured":"Weir, G. M. et al. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. J. Immunother. Cancer 4, 68 (2016).","journal-title":"J. Immunother. Cancer"},{"key":"72125_CR27","doi-asserted-by":"publisher","first-page":"3030","DOI":"10.1200\/jco.2013.31.15_suppl.3030","volume":"31","author":"NL Berinstein","year":"2013","unstructured":"Berinstein, N. L. et al. Effect of oral cyclophosphamide on the immunogenicity of DPX-Survivac in ovarian cancer patients: results of a phase I study. J. Clin. Oncol. 31, 3030 (2013).","journal-title":"J. Clin. Oncol."},{"key":"72125_CR28","doi-asserted-by":"publisher","first-page":"5555","DOI":"10.1200\/jco.2014.32.15_suppl.5555","volume":"32","author":"M Wilson","year":"2014","unstructured":"Wilson, M. et al. Phase I\/Ib clinical and immunologic assessment of immunotherapeutic vaccine, DPX-Survivac in women with ovarian, Fallopian tube, or peritoneal cancer (OC). J. Clin. Oncol. 32, 5555 (2014).","journal-title":"J. Clin. Oncol."},{"key":"72125_CR29","doi-asserted-by":"publisher","first-page":"2808","DOI":"10.1158\/1078-0432.CCR-22-2595","volume":"29","author":"O Dorigo","year":"2023","unstructured":"Dorigo, O. et al. Maveropepimut-S, a DPX-based immune-educating therapy, shows promising and durable clinical benefit in patients with recurrent ovarian cancer, a phase II trial. Clin. Cancer Res. 29, 2808\u20132815 (2023).","journal-title":"Clin. Cancer Res."},{"key":"72125_CR30","doi-asserted-by":"publisher","first-page":"6075","DOI":"10.1200\/JCO.2020.38.15_suppl.6075","volume":"38","author":"O Dorigo","year":"2020","unstructured":"Dorigo, O. et al. Infiltration of tumor by T cells following treatment with DPX-Survivac and intermittent low dose cyclophosphamide (CPA) leads to clinical responses in advanced recurrent ovarian cancer (OvCa). J. Clin. Oncol. 38, 6075 (2020).","journal-title":"J. Clin. Oncol."},{"key":"72125_CR31","doi-asserted-by":"publisher","first-page":"e1026529","DOI":"10.1080\/2162402X.2015.1026529","volume":"4","author":"NL Berinstein","year":"2015","unstructured":"Berinstein, N. L. et al. Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. OncoImmunology 4, e1026529 (2015).","journal-title":"OncoImmunology"},{"key":"72125_CR32","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1200\/JCO.2018.36.15_suppl.5510","volume":"36","author":"O Dorigo","year":"2018","unstructured":"Dorigo, O. et al. Clinical data from the DeCidE1 trial: assessing the first combination of DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with stage IIc-IV recurrent epithelial ovarian cancer. J. Clin. Oncol. 36, 5510 (2018).","journal-title":"J. Clin. Oncol."},{"key":"72125_CR33","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1182\/blood-2019-125963","volume":"134","author":"NL Berinstein","year":"2019","unstructured":"Berinstein, N. L. et al. Combination of DPX-Survivac, low dose cyclophosphamide, and pembrolizumab in recurrent\/refractory DLBCL: the Spirel study. Blood 134, 3236 (2019).","journal-title":"Blood"},{"key":"72125_CR34","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1158\/0008-5472.CAN-12-4100","volume":"73","author":"J Duraiswamy","year":"2013","unstructured":"Duraiswamy, J., Kaluza, K. M., Freeman, G. J. & Coukos, G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 73, 3591\u20133603 (2013).","journal-title":"Cancer Res"},{"key":"72125_CR35","doi-asserted-by":"publisher","first-page":"v494","DOI":"10.1093\/annonc\/mdz253.034","volume":"30","author":"HJ Conter","year":"2019","unstructured":"Conter, H. J. et al. Safety and efficacy results of the combination of DPX-Survivac, pembrolizumab and intermittent low dose cyclophosphamide (CPA) in subjects with advanced and metastatic solid tumours: preliminary results from the hepatocellular carcinoma (HCC), NSCLC, bladder cancer, & MSI-H cohorts. Ann. Oncol. 30, v494 (2019).","journal-title":"Ann. Oncol."},{"key":"72125_CR36","doi-asserted-by":"publisher","first-page":"CT035","DOI":"10.1158\/1538-7445.AM2022-CT035","volume":"82","author":"O Rixe","year":"2022","unstructured":"Rixe, O. et al. Abstract CT035: safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer. Cancer Res. 82, CT035 (2022).","journal-title":"Cancer Res."},{"key":"72125_CR37","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine, E. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32, 1302\u20131308 (2014).","journal-title":"J. Clin. Oncol."},{"key":"72125_CR38","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3390\/vaccines8040657","volume":"8","author":"S Chow","year":"2020","unstructured":"Chow, S., Berek, J. S. & Dorigo, O. Development of therapeutic vaccines for ovarian cancer. Vaccines 8, 657 (2020).","journal-title":"Vaccines"},{"key":"72125_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/ejh.13982","volume":"111","author":"I Amitai","year":"2023","unstructured":"Amitai, I. et al. PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R\/R DLBCL. Eur. J. Haematol. 111, 191\u2013200 (2023).","journal-title":"Eur. J. Haematol."},{"key":"72125_CR40","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11060-021-03695-w","volume":"152","author":"SL Duong","year":"2021","unstructured":"Duong, S. L., Barbiero, F. J., Nowak, R. J. & Baehring, J. M. Neurotoxicities associated with immune checkpoint inhibitor therapy. J. Neurooncol. 152, 265\u2013277 (2021).","journal-title":"J. Neurooncol."},{"key":"72125_CR41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3892\/mco.2022.2553","volume":"17","author":"G Inui","year":"2022","unstructured":"Inui, G. et al. Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: a case report and literature review of aseptic meningitis as an immune-related adverse event. Mol. Clin. Oncol. 17, 120 (2022).","journal-title":"Mol. Clin. Oncol."},{"key":"72125_CR42","doi-asserted-by":"publisher","first-page":"100885","DOI":"10.1016\/j.gore.2021.100885","volume":"38","author":"D Noguchi","year":"2021","unstructured":"Noguchi, D. et al. A case of relapsing aseptic meningitis under excellent tumor response to pembrolizumab in microsatellite instability-high recurrent endometrial cancer. Gynecol. Oncol. Rep. 38, 100885 (2021).","journal-title":"Gynecol. Oncol. Rep."},{"key":"72125_CR43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/ckj\/sfy100","volume":"12","author":"H Izzedine","year":"2019","unstructured":"Izzedine, H. et al. Renal toxicities associated with pembrolizumab. Clin. Kidney J. 12, 81\u201388 (2019).","journal-title":"Clin. Kidney J."},{"key":"72125_CR44","doi-asserted-by":"publisher","first-page":"S546","DOI":"10.1016\/j.annonc.2024.08.775","volume":"35","author":"O Klein","year":"2024","unstructured":"Klein, O. et al. 713MO Nivolumab and ipilimumab combination treatment in advanced gynaecological clear cell cancers: results from the phase II MoST-CIRCUIT trial. Ann. Oncol. 35, S546\u2013S547 (2024).","journal-title":"Ann. Oncol."},{"key":"72125_CR45","doi-asserted-by":"publisher","first-page":"LBA5500","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5500","volume":"42","author":"DS Dizon","year":"2024","unstructured":"Dizon, D. S. et al. Final results of BrUOG 354: a randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas. J. Clin. Oncol. 42, LBA5500 (2024).","journal-title":"J. Clin. Oncol."},{"key":"72125_CR46","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1136\/ijgc-2022-003430","volume":"32","author":"TY Sia","year":"2022","unstructured":"Sia, T. Y. et al. Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series. Int. J. Gynecol. Cancer 32, 1017\u20131024 (2022).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"72125_CR47","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/2326-6066.CIR-22-0407","volume":"10","author":"M-J Devlin","year":"2022","unstructured":"Devlin, M.-J. et al. The tumor microenvironment of clear-cell ovarian cancer. Cancer Immunol. Res. 10, 1326\u20131339 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"72125_CR48","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3390\/cancers15051458","volume":"15","author":"BL Manning-Geist","year":"2023","unstructured":"Manning-Geist, B. L. et al. Phase I study of a multivalent WT1 peptide vaccine (Galinpepimut-S) in combination with nivolumab in patients with WT1-expressing ovarian cancer in second or third remission. Cancers 15, 1458 (2023).","journal-title":"Cancers"},{"key":"72125_CR49","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22.01900","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis, U. A. et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J. Clin. Oncol. 41, 2436\u20132445 (2023).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72125-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72125-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72125-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:03:26Z","timestamp":1784246606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72125-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72125"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72125-0","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C.V.: Honoraria from AstraZeneca and Merck Sharp & Dhome; Consultancy\/advisor role from Merck Sharp & Dhome outside the submitted work. S.L.: Institutional funding for clinical trials as PI from AstraZeneca, Merck Sharp & Dhome, Repare Therapeutics, Seagen, Schrodinger, GSK and Roche. Consultancy\/advisor role from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dhome, AbbVie, Eisai, Zai Lab, Gilead, outside the submitted work. I.C.: declares institutional funding for clinical trials as PI from AstraZeneca, Merck Sharp & Dhome, Vivesto, Tolremo, Orion, Bayer, lncyte; consultancy\/advisor role from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dhome, AbbVie, Biontech, lncyte, outside the submitted work. A.M.: Honoraria from AstraZeneca,\u00a0AbbVie, Daichii Sankyo, Eisai, GSK, MSD, Lilly and Pharma. A.M.O.: PI and Steering Committees with AstraZeneca, GSK. Advisory to Abbvie, CEO in Ozmosis Research. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6416"}}